Chonluten is a synthetic peptide of three amino acids, a tripeptide. It belongs to a family of short organ-specific peptides that Russian researchers extracted from animal tissue and then rebuilt by chemical synthesis [1][8]. No parent protein is named in the literature. The peptide was isolated from Langopept, a peptide preparation made from bronchial tissue, and a 2020 paper from the same program describes the wider effort to identify short peptides inside organ extracts [7][12]. The Russian literature classes it as a peptide bioregulator, a short organ-specific peptide studied for its effects on gene expression [1][2].
Chonluten comes from the St. Petersburg peptide program that Vladimir Khavinson's group has worked on since 1973 [1]. The group extracted polypeptide complexes from animal organs, identified short peptides inside them, and synthesized the fragments for study [1][8]. The bronchial member of that set was named Chonluten and made as a tripeptide, while the same molecule appears in older papers as T-34 [6][7]. That second name matters for anyone reading the literature, because the skin and gene-expression work sits under T-34 and the lung work sits under Chonluten [5][6][7].
The research case rests on two promises: helping bronchial epithelium repair itself and damping inflammatory signaling [1][2][7]. The evidence is early: organotypic cultures of rat tissue, a gastric ulcer report, one human monocyte cell line and computer docking models [1][4][5]. The effects are modest and tissue-specific [7][9][11]. As of October 2026, Chonluten has no FDA-approved drug product and no clinical trial registered on ClinicalTrials.gov, and neither the WADA Prohibited List nor the NCAA banned-substances list names it [13][14].
Key takeaways
- Chonluten is a three-amino-acid peptide from the St. Petersburg peptide-bioregulator program, and the literature also calls it T-34 [1][6][7].
- In rat tissue explants it raised outgrowth in lung by 21 to 24 percent [7][8], pancreas by 18 to 21 percent [11], and vessel and muscle by 21 and 29 percent [9], while skin explants from young rats and bronchial artery tissue showed no significant response [6][7].
- The human clinical record is a single 2020 review statement about oral use in bronchopulmonary disease, and the clinical sentences carry no trial citation [2].
How it works
Cell entry through amino acid and peptide transporters
The main model proposed for Chonluten's entry is that it uses the same transporters that carry amino acids and small peptides. LAT1 is a transporter on the cell surface that moves large neutral amino acids such as leucine and tryptophan into cells. PEPT1 is a transporter that carries dipeptides and tripeptides, the two- and three-amino-acid products of protein digestion, across the membrane of intestinal and other epithelial cells [3][4].
Computer docking puts Chonluten among the stronger peptide binders of the amino acid carriers, with a middle-of-the-set score for PEPT1. A docking score is a computed estimate of binding strength, and more negative values mean tighter predicted binding. In a 2023 study of 26 short peptides, Chonluten ranked second for LAT1 with a score of -43.40, behind a related tripeptide at -45.32, and it ranked eighth for LAT2, fifteenth for PEPT1 and tenth for PEPT2 [4]. A 2022 review reported a LAT1 score of -30.30 for the same peptide; docking scores depend on the receptor structure and the scoring setup, so the two numbers are not directly comparable [3][4]. The 2023 authors propose that tight binding could also block the transporter and interfere with the uptake of other substrates, a hypothesis they did not test at the bench [4].
The transport idea fits the oral use described for Chonluten. A tripeptide is small enough for PEPT1, and the review that lists Chonluten among transporter ligands treats carrier-mediated uptake as the plausible route into cells [3]. No experiment in the verified literature measures how much intact peptide crosses a human gut wall or reaches lung tissue. The docking scores are predictions, and the papers present them as preliminary [4].
MAP kinase and STAT signaling in human monocytes
In a human monocyte cell line, Chonluten changed both growth signaling and inflammatory output. Monocytes are white blood cells that patrol the blood and become macrophages in tissue. MAP kinases, including ERK and JNK, are enzyme cascades that carry growth and stress signals from the cell surface to the nucleus. STAT1 is a transcription factor that moves into the nucleus after phosphorylation, the addition of a phosphate group, and switches on immune genes [1].
The experiment used THP-1 cells, a line derived from a human leukemia, at 100 nanograms per milliliter of peptide. Chonluten raised tyrosine phosphorylation of ERK1/2 and JNK in resting monocytes, and it raised STAT1 phosphorylation and nuclear translocation in macrophage-like cells [1]. In the same study, Chonluten on its own produced a slight release of TNF, a pro-inflammatory cytokine, and a moderate but consistent apoptotic fraction among proliferating cells [1]. When the cells were stimulated with LPS, a bacterial molecule that triggers inflammation, Chonluten lowered TNF and IL-6 output and reduced monocyte adhesion to activated human endothelial cells [1].
The authors read the pattern as TNF tolerance: a small, controlled TNF signal that leaves the cells less responsive to a later inflammatory hit [1]. That interpretation is a hypothesis built on one cell line at one concentration. Cytokine values appear in figures, not as numbers in the text, and the paper does not identify the surface molecule that starts the response [1].
Gene expression and antioxidant proteins
A second line of work says Chonluten acts on gene expression, the process by which a cell reads a gene and builds its protein. A 2012 paper on gastric ulcer reports that the peptide it calls T-34 normalized the synthesis of antioxidant and anti-inflammatory proteins by regulating the expression of the corresponding genes [5]. Antioxidant proteins neutralize reactive oxygen species, the damaging by-products of normal metabolism and inflammation. The abstract does not name the genes, the animal species or the dose [5].
A 2020 review from the same research group names a specific gene set. It attributes to Chonluten the regulation of c-Fos, HSP70, the antioxidant enzyme SOD, COX-2 and TNF-alpha, and links that gene control to the peptide's stress-protective effect [2]. c-Fos is an immediate-early gene that turns on after stress, HSP70 is a chaperone that protects proteins from unfolding, and COX-2 is an enzyme that drives inflammatory prostaglandins. The review cites the 2012 gene-expression paper for the gene list, and that paper's abstract supports the general claim about antioxidant and anti-inflammatory proteins, not each named gene [2][5].
This is the mechanism the Russian literature treats as central: a short peptide enters the cell and shifts the expression of a set of protective genes [2][5]. The 2022 transport review and the 2023 docking paper support the entry step in models. No study in the verified set measures the antioxidant protein products in human tissue, and none ties a specific gene change to a clinical effect [4][5].
Tissue-specific growth in organotypic culture
The most consistent laboratory effect is a small increase in the outgrowth of certain tissue explants. An organotypic culture keeps a piece of living tissue alive on a dish or membrane, and the area index is the total area of the explant including its growth zone divided by the area of its central zone. A rise in the area index means cells at the edge are migrating or dividing faster than in untreated tissue [7][8].
Chonluten raised the area index of rat lung explants by 21 percent in a 2025 study and by 24 percent in a 2024 study [7][8]. In the 2025 experiment it did not significantly change bronchial or bronchial artery explants, and in a 2022 experiment it raised vessel explants by 21 percent and muscle explants by 29 percent [7][9]. Pancreas explants rose 18 percent in young rats and 21 percent in old rats in a 2023 study [11]. The 2022 experiment used 0.05 nanograms per milliliter, the 2024 experiment used 20 nanograms per milliliter for the tripeptide, and the 2025 lung study used 1 nanogram per milliliter [7][8][9].
The variation is the point. Skin explants showed no proliferation response to T-34 in young rats, and testis explants responded in young animals [6][10]. A peptide that acts on one tissue and not another fits the organ-specific claim of the bioregulator family, and it also means a result in lung tissue says little about skin or airway smooth muscle [1][7].
No receptor for Chonluten has been identified. The THP-1 authors propose that the peptides act without a ligand-receptor interaction, and the transporter work offers an entry route rather than a signaling receptor [1][4]. Until a target is found, the mechanism remains a set of plausible steps rather than a chain of cause and effect.
What has been studied in humans
As of October 2026, no clinical trial of Chonluten has been registered on ClinicalTrials.gov or published in the indexed literature. An indexed-literature search on October 23, 2026 returned three papers that name the peptide: the THP-1 cell study and two reviews [1][2][3]. A ClinicalTrials.gov search on the same day returned no study. The human evidence therefore consists of human cells in culture and a review's summary of Russian clinical use.
The review statement is specific about the setting and vague about the data. It says oral Chonluten was effective for bronchopulmonary pathology, including chronic obstructive pulmonary disease and chronic bronchitis with an asthmatic component, and that it raised a physical-performance index under low oxygen partial pressure [2]. It also says the peptide enhanced standard therapy in chronic bronchitis with an asthmatic component [2]. It gives no dose, duration, number of patients, endpoint definition or adverse-event count.
The clinical sentences carry no trial citation. The paragraph's only citation points to a 2012 paper on gene expression in gastric ulcer, which is not a clinical study [2][5]. The review is written by Khavinson and colleagues, the group that developed the peptide, which makes an independent trial report the missing piece rather than a confirmatory detail [1][2].
The human cell work is more concrete but still not a human study. THP-1 is a leukemia-derived monocyte line, and the endothelial cells in the adhesion assay came from human umbilical veins [1]. Those experiments show that human cells respond to the peptide at 100 nanograms per milliliter, and they say nothing about absorption, lung concentration or clinical benefit [1].
A first human study would need to measure plasma and lung exposure, a lung-function or inflammatory endpoint, and adverse events. None of that exists in the verified record. The gap is the central fact about Chonluten as a clinical candidate, and it is why the review's claims stay leads rather than results [2].
Doses studied in human trials
As of October 2026, Chonluten remains without an FDA-approved drug product or a clinical trial registered on ClinicalTrials.gov. The studies below are the laboratory and animal experiments that carry the evidence.
100 ng/mL
THP-1 human monocytic leukemia cells and THP-1-derived macrophages, with human umbilical vein endothelial cells in the adhesion assay
1 ng/mL
Lung, bronchus and bronchial artery explants from 3-month-old Wistar rats (230 lung, 200 bronchus and 210 bronchial artery explants)
20 ng/mL
Lung explants from 5-month-old Wistar rats (400 explants)
0.05 ng/mL
Explants of skin, myocardium, prostate, testis, vessels, muscle and bladder from 3-month-old Wistar rats (560 explants)
1 ng/mL
Pancreas explants from 3-month-old and 18-month-old Wistar rats (400 explants); cartilage, kidney and testis were also cultured
Lab and animal studies
Preclinical means work in cells, tissue or animals before a treatment reaches human testing. For Chonluten the base is nine preclinical papers, most from one laboratory network in St. Petersburg and its collaborators in Italy [1][7][9]. The methods are narrow: organotypic explant cultures, one monocyte line, docking and gene-expression assays.
The lung work is the most directly relevant to the peptide's name. In the 2025 study, lung, bronchus and bronchial artery tissue from 3-month-old Wistar rats was cultured with 1 nanogram per milliliter of peptide for three days [7]. Chonluten raised the lung area index by 21 percent, with no significant change in bronchus or bronchial artery [7]. The 2024 study used 5-month-old rats and 20 nanograms per milliliter and reported a 24 percent rise in lung explants; adding a dipeptide produced area-index increases of 40 and 44 percent [8].
The vessel and muscle result comes from the 2022 magnetic-field experiment. Chonluten at 0.05 nanograms per milliliter raised vessel explants by 21 percent and muscle explants by 29 percent, and it had no stimulating effect on the other tissues tested [9]. That study was built to test weak static magnetic fields, so the peptide arms are a side comparison rather than the main design.
Pancreas and testis explants extend the tissue map. In pancreas, Chonluten raised the area index by 18 percent in 3-month-old rats and 21 percent in 18-month-old rats, and combinations with the amino acid proline raised it further [11]. In testis, the effect appeared in young rats, and the authors describe tripeptide effects as dependent on tissue and age [10]. Skin was the exception from the start: in 2012, T-34 was the one tripeptide of five that did not stimulate proliferation in skin explants from young rats [6].
The gastric ulcer paper is the only one in the set that addresses a disease. T-34 normalized the synthesis of antioxidant and anti-inflammatory proteins by regulating gene expression, according to the abstract [5]. The abstract does not name the model, the species, the dose or the genes, so the result establishes a direction rather than a mechanism. A 2025 paper cites this study for Chonluten's antioxidant and anti-inflammatory activity, which is how the connection to the current literature is made [7].
The docking work adds a testable entry route. Chonluten binds LAT1, LAT2, PEPT1 and PEPT2 in models, with the strongest score at LAT1 [3][4]. The same calculations suggest it could inhibit those transporters, which would be a mechanism with consequences beyond the peptide's own uptake [4]. None of this has been checked against measured transport in cells.
Research in detail
In vitro human cell-line experiment with LPS stimulation, flow cytometry and Western blot · THP-1 human monocytic leukemia cells and THP-1-derived macrophages, with human umbilical vein endothelial cells in the adhesion assay
At 100 nanograms per milliliter, Chonluten raised ERK1/2 and JNK phosphorylation, raised STAT1 phosphorylation and nuclear translocation, produced a slight TNF release on its own and a moderate apoptotic fraction, and lowered TNF and IL-6 in LPS-stimulated macrophages; monocyte adhesion to activated endothelial cells fell.
Evidence scope: One immortalized leukemia cell line at one concentration; cytokine values are shown as figures without numbers; the receptor or initiating molecule is not identified.
Organotypic explant culture of three respiratory tissues with morphometric area-index measurement · Lung, bronchus and bronchial artery explants from 3-month-old Wistar rats (230 lung, 200 bronchus and 210 bronchial artery explants)
Chonluten at 1 nanogram per milliliter raised the lung explant area index by 21 percent over control; bronchus and bronchial artery explants showed no significant change.
Evidence scope: Explants only, so the area index measures outgrowth rather than repair in a living animal; no pharmacokinetics, toxicity or human data.
Organotypic explant culture with single peptides and dipeptide plus tripeptide combinations · Lung explants from 5-month-old Wistar rats (400 explants)
Chonluten alone raised the lung explant area index by 24 percent; with one dipeptide it rose 40 percent and with the other it rose 44 percent.
Evidence scope: Explants only; the paper's discussion mislabels Chonluten as a different tripeptide, so the assignment rests on its tables and the other papers.
Organotypic explant culture with weak static magnetic field arms and peptide arms · Explants of skin, myocardium, prostate, testis, vessels, muscle and bladder from 3-month-old Wistar rats (560 explants)
Chonluten at 0.05 nanograms per milliliter raised vessel explant outgrowth by 21 percent and muscle explant outgrowth by 29 percent, with no significant effect on the other tissues tested.
Evidence scope: The study was designed around magnetic fields, so the peptide arms are a secondary comparison; explants only, with no toxicity or pharmacokinetic data.
Organotypic explant culture of pancreas, cartilage, kidney and testis with peptide and amino acid combinations; the pancreas arm is reported here · Pancreas explants from 3-month-old and 18-month-old Wistar rats (400 explants); cartilage, kidney and testis were also cultured
Chonluten at 1 nanogram per milliliter raised the pancreas explant area index by 18 percent in young rats and 21 percent in old rats; adding proline raised the area index to 35 percent in young rats and 34 percent in old rats.
Evidence scope: The pancreas arm is one of four tissues in the study; the area index measures tissue outgrowth, not organ function, and no functional endpoint is reported.
Organotypic skin explant culture with five synthetic tripeptides and p53 immunocytochemistry · Skin explants from young and old rats
All five tripeptides except T-34 stimulated proliferation in skin from young rats; T-38 produced a marked effect in skin from old rats. The authors attributed the proliferation changes to reduced apoptosis.
Evidence scope: Abstract only; doses and group sizes are not reported, and a negative skin result does not rule out effects in other tissues.
Gene-expression and protein readouts in a gastric ulcer context · Species and model details not stated in the abstract
The geroprotective peptide T-34 normalized the synthesis of antioxidant and anti-inflammatory proteins by regulating expression of the corresponding genes.
Evidence scope: Abstract only; the species, model details, dose, group sizes and specific genes are not reported.
History and where it stands today
Chonluten's record runs from a 1973 tissue-extract program to a small modern literature on lung explants and cell signaling.
- 1973Vladimir Khavinson's group in St. Petersburg began studying organ-specific short peptides isolated from animal tissue, the program that produced Chonluten [1].
- 2012Two papers report on T-34, the code used for this tripeptide: one describes normalized antioxidant and anti-inflammatory protein synthesis in a gastric ulcer study, and the other reports no skin-cell proliferation response in young rats [5][6].
- 2020A review from the group states that oral Chonluten was used for bronchopulmonary disease and improved physical performance under low oxygen, and its clinical sentences carry no trial citation [2]. A separate 2020 paper reports short-peptide identification in organ extracts [12].
- 2022The THP-1 study reports MAP kinase and STAT1 activation plus lower inflammatory cytokine output, and a docking review ranks Chonluten among the strongest LAT1 ligands [1][3]. The magnetic-field study reports 21 percent more vessel outgrowth and 29 percent more muscle outgrowth [9].
- 2023A docking study of 26 peptides ranks Chonluten second for LAT1, and a pancreas explant study reports 18 percent growth in young rats and 21 percent in old rats [4][11].
- 2024Lung explants grow 24 percent more with Chonluten, and combinations with two dipeptides produced area-index increases of 40 and 44 percent [8].
- 2025Lung explants grow 21 percent more, while bronchial and bronchial artery explants show no significant change [7].
- October 2026Chonluten remains without an FDA-approved drug product and without a clinical trial registered on ClinicalTrials.gov, and it is not named by WADA or the NCAA [13][14]. FDA's compounding safety-risk list names Epitalon, a related peptide, but not Chonluten [15]. The NCAA page explains how PeptidePrices classifies the peptide class.
How it compares with related peptides
Bronchogen is a tetrapeptide from the same peptide family and the same bronchial target, and the 2020 review pairs it with Chonluten as a bronchopulmonary peptide [2]. Bronchogen is one amino acid longer and is described as regulating gene expression and protein synthesis in lung cells, while Chonluten's direct lung data are explant outgrowth measurements [2][7]. The Bronchogen page covers the tetrapeptide side.
Epitalon is the tetrapeptide from the same family, and it appears alongside Chonluten in the THP-1 and transporter studies [1][4]. In the THP-1 experiment both peptides activated STAT1 and lowered inflammatory cytokines, and the docking study scored both against the same carriers [1][4]. Chonluten is a tripeptide tied to bronchial tissue, while Epitalon is a tetrapeptide from the same program [1][2]. See Epitalon.
Cardiogen is a tetrapeptide studied for heart and vessel tissue, and it ran in the same 2022 explant experiment as Chonluten [9]. Cardiogen raised myocardium outgrowth by 24 percent and vessel outgrowth by 20 percent, while Chonluten raised vessel outgrowth by 21 percent and muscle outgrowth by 29 percent [9]. The comparison shows how narrowly the family's tissue preferences run. Cardiogen covers the cardiac side.
Side effects and safety signals
The safety record for Chonluten is thin: no human trial has reported adverse events, and no animal toxicology program appears in the verified literature.
- No human adverse events are reported in the verified literature: no clinical trial has been published, and the 2020 review describes clinical use without an adverse-event count [2].
- In THP-1 cells, Chonluten produced a moderate but consistent apoptotic fraction among proliferating monocytes, a signal in a leukemia-derived cell line rather than a finding in animals or humans [1].
- No toxicology: the reports reviewed describe no dose-ranging study, organ histology, clinical chemistry or a mortality endpoint [5][7][9].
- No pharmacokinetics: no study in the verified set measures Chonluten's absorption, distribution, metabolism or clearance in any species, and the oral use in the review gives no dose or blood level [2].
- Transporter binding is a theoretical safety question: if Chonluten inhibits LAT1 or PEPT1, it could interfere with amino acid or dipeptide uptake, and the docking paper raises this as a possibility [4].
- Immunogenicity and aggregation are unmeasured for Chonluten, and FDA's review of Epitalon, a related peptide, flags aggregation and peptide-related impurities as concerns for that peptide [15].
- Identity and purity rest on the certificate of analysis for a research batch, and the COA library explains the tests that matter for a short peptide.
The future: what's next for Chonluten
No trial is registered on ClinicalTrials.gov, so the next step is a first-in-human study rather than a phase 3 readout. A ClinicalTrials.gov search on October 23, 2026 returned no Chonluten study, and the 2020 review's clinical claims have no registry entry behind them [2]. A credible study would need a defined dose, a measured exposure, a lung or inflammatory endpoint, and a safety arm.
The regulatory calendar is empty. Chonluten has no FDA-approved drug product, and it does not appear on FDA's compounding safety-risk list, which names Epitalon instead [15]. No pending FDA action appears in the sources reviewed. WADA and the NCAA do not name it, which leaves the class language as the only sport rule that applies [13][14].
The research questions are mostly about delivery and target. Bronchial tissue is where the peptide was isolated from, and the explant data are the only direct lung evidence [7][8]. Transporters are the best-supported entry route, and the docking predictions need measured uptake in human airway cells [4]. A pharmacokinetic study in animals would tell the field whether the nanogram-per-milliliter concentrations used in culture are reachable in tissue.
- Whether Chonluten reaches lung tissue intact after oral use, and what fraction of a dose arrives there.
- Which transporter carries it across human airway epithelium, and whether binding inhibits the transport of other peptides or amino acids.
- Whether the explant outgrowth results translate into repair in a living animal or a human airway.
- Why the response differs by tissue and by age, and which cell type in the explant is responding.
- Whether the TNF and IL-6 changes in THP-1 cells reflect a real anti-inflammatory effect or a cell-line artifact.